首页> 美国卫生研究院文献>Saudi Pharmaceutical Journal : SPJ >In-vitro and in-vivo evaluation of repaglinide loaded floating microspheres prepared from different viscosity grades of HPMC polymer
【2h】

In-vitro and in-vivo evaluation of repaglinide loaded floating microspheres prepared from different viscosity grades of HPMC polymer

机译:由不同粘度等级的HPMC聚合物制备的载有瑞格列奈的漂浮微球的体外和体内评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

During the study repaglinide encapsulated floating microspheres were formulated and characterized for enhancing residence time of drug in git and thereby increasing its bioavailability. Floating microspheres of ethylcellulose (EC) and hydroxypropyl methyl cellulose (HPMC) (5 and 100 cps) were prepared by emulsion solvent diffusion technique. During process optimization various parameters were studied such as: drug: polymer ratio, polymer ratio, concentration of emulsifier and stirring speed. Selected optimized formulations were studied for SEM, entrapment, floating behavior, drug release and kinetics. In-vivo floating ability (X-ray) study and in-vivo antidiabetic activity were performed on alloxan induced diabetic rats. Microspheres prepared with different viscosity grade HPMC were spherical shaped with smooth surface. Size of microspheres was in the range of 181.1–248 μm. Good entrapment and buoyancy were observed for 12 h. X-ray image showed that optimized formulation remained buoyant for more than 6 h. Optimized formulation treated group shows significant (p < 0.01) reduction in blood glucose level as compared to pure drug treated group. Repaglinide loaded floating microspheres expected to give new choice for safe, economical and increased bioavailable formulation for effective management of NIDDM.
机译:在研究过程中,配制了瑞格列奈封装的漂浮微球,并对其进行了表征,以延长药物在git中的停留时间,从而提高其生物利用度。通过乳液溶剂扩散技术制备了乙基纤维素(EC)和羟丙基甲基纤维素(HPMC)(5和100cps)的漂浮微球。在工艺优化过程中,研究了各种参数,例如:药物:聚合物比率,聚合物比率,乳化剂浓度和搅拌速度。研究了选定的优化配方的SEM,截留,漂浮行为,药物释放和动力学。在四氧嘧啶诱导的糖尿病大鼠上进行了体内漂浮能力(X射线)研究和体内抗糖尿病活性。用不同粘度等级的HPMC制备的微球为球形,表面光滑。微球的尺寸在181.1–248μm的范围内。观察到良好的包裹性和浮力持续12小时。 X射线图像显示优化配方的浮力保持超过6小时。优化制剂治疗组与纯药物治疗组相比,血糖水平显着降低(p <0.01)。瑞格列奈负载的漂浮微球有望为安全,经济和增加生物利用度的配方提供新的选择,以有效管理NIDDM。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号